Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.47 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21111208 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL17979421 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18068173 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL16635282 | 0.81 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL21174908 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL18018417 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL21012768 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL20281091 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL20280993 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL22468371 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922392-B | 1- (hetero) arylsulfonyl- (pyrrolidine or piperidine) -2-carboxamide derivatives and uses thereof | 豪夫迈·罗氏有限公司 | 2020-07-21 | — | — | CN | disclosed |
| EP-3256463-B1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2019-10-09 | — | — | EP | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-3256463-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-12-20 | — | — | EP | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128529-A1 | 1-(HET)ARYLSULFONYL-(PYRROLIDINE OR PIPERIDINE)-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS TRPA1 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | SMN1; SMN2 1143/4885NPC1 1665/4885RAB9A 1263/4885 |
| US-20160264567-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | TRPA1, TRPV1, TRPV5 | SMN1; SMN2 1143/4885NPC1 1665/4885RAB9A 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.